New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
05:41 EDTBIIBBiogen, Eisai enter collaboration develop, commercialize Alzheimerís treatments
Eisai and Biogen Idec announced that they have entered into a collaboration to develop and commercialize two of Eisaiís clinical candidates for Alzheimerís disease, or AD, E2609 and BAN2401. The agreement also provides Eisai with an option to jointly develop and commercialize two of Biogen Idecís candidates for AD, the anti-amyloid beta antibody BIIB037 and an anti-tau monoclonal antibody. The collaboration initially will be centered on the co-development and co-commercialization of Eisaiís two candidates: E2609, a beta-site amyloid precursor protein cleaving enzyme, or BACE, inhibitor, and BAN2401, an anti-amyloid beta antibody. These candidates have the potential to reduce amyloid beta plaques that form in the brains of patients with AD and to stop the formation of new plaques, potentially improving symptoms and suppressing disease progression. Biogen Idec will provide Eisai with an upfront payment and a fixed amount of development, approval and commercial milestone payments. The agreement also includes options for Eisai to receive an additional one-time payment from Biogen Idec related to joint development and commercialization activities in Japan.
News For BIIB From The Last 14 Days
Check below for free stories on BIIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2014
13:41 EDTBIIBCitigroup to hold a conference
Subscribe for More Information
August 27, 2014
09:08 EDTBIIBNektar could see $100M in revenue from Baxter drug, says Roth Capital
Roth Capital believes that Baxter's (BAX) BAX-855 drug delivered compelling Phase III data, and the firm expects the drug to compete effectively against Biogen's (BIIB) Eloctate. Roth expects BAX-855 to launch in 1Q16 and believes it could generate up to $100M in annual revenue for Nektar. The firm keeps a $21 price target and Buy rating on Nektar.
08:21 EDTBIIBNICE recommends Tecfidera for multiple sclerosis
Dimethyl fumarate is recommended as a possible treatment for people with active relapsing-remitting multiple sclerosis that isn't highly active or rapidly evolving severe relapsing-remitting multiple sclerosis, the U.K.'s National Institute for Health and Care Excellence stated in guidance posted to its website. Reference Link
August 26, 2014
11:21 EDTBIIBBiogen added to short term buy list at Deutsche Bank
August 22, 2014
12:39 EDTBIIBThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use